The lack of access to a new drug for muscular dystrophy in Northern Ireland has left a 12-year-old boy, Alfie, and his family in a difficult situation. Alfie was diagnosed with Duchenne muscular dystrophy (DMD) at the age of four. The new drug, Givinostat, has the potential to slow down the progression of his condition, but the Belfast Trust is unable to offer it due to staffing constraints.
According to Mr. Pentony, Alfie’s father, there are 13 boys in Northern Ireland who could benefit from Givinostat. The delay in providing this treatment is concerning, as time is crucial when it comes to Duchenne muscular dystrophy. The Belfast Trust cited the need for additional resources to ensure the safe implementation of the drug, which has left families feeling frustrated and disappointed.
Muscular dystrophy encompasses various genetic conditions that lead to muscle weakening and disability over time. DMD, one of the most severe forms, typically affects boys in early childhood and reduces life expectancy significantly. Despite the approval of Givinostat by the UK medicines regulator for early access, individual trusts must apply to participate in the Early Access Programme, causing delays for patients like Alfie.
Una Farrell from Duchenne UK expressed frustration at the lack of access to a potentially life-changing treatment for children with muscular dystrophy. The slow progression of decisions regarding Givinostat’s wider access has added to the anxiety and uncertainty faced by families dealing with this debilitating condition. The hope for routine access to the drug in health services hinges on guidance from assessment bodies like NICE, but the timeline for such decisions remains uncertain
Read the full article from The BBC here: Read More
